Dr. Ashwin Somasundaram
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Texas Southwestern Medical School at Dallas (2013)
- Years since graduation
- 13
- In the NPI registry since
- 2013
- Medicare patients seen, 2024
- 89
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2013Medical school: University of Texas Southwestern Medical School at Dallas
- 2013Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
NC license 2021-02889
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Unc Hospitals Chapel Hill, NC
- Rex Hospital Raleigh, NC
Medical groups
- University of North Carolina at Chapel Hill (2,052 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 89
- Services billed
- 385
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 237 | 82 |
| New patient office or other outpatient visit, 60-74 minutes | 31 | 31 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ondansetron Hcl Other prescribers in Pittsburgh, PA | 68 |
| Dexamethasone Other prescribers in Pittsburgh, PA | 64 |
| Prochlorperazine Maleate Other prescribers in Pittsburgh, PA | 64 |
| Mirtazapine Other prescribers in Pittsburgh, PA | 39 |
| Pantoprazole Sodium Other prescribers in Pittsburgh, PA | 29 |
| Oxycodone Hcl Other prescribers in Pittsburgh, PA | 27 |
| Eliquis (apixaban) Other prescribers in Pittsburgh, PA | 20 |
| Xarelto (rivaroxaban) Other prescribers in Pittsburgh, PA | 18 |
| Loperamide (loperamide hcl) Other prescribers in Pittsburgh, PA | 17 |
| Prednisone Other prescribers in Pittsburgh, PA | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 2 payments worth $199 in total to this clinician.
| Caris Mpi, Inc. | $130 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $68.49 |
| Food and Beverage | $130 |
|---|---|
| Education | $68.49 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Jul 30, 2025 | Education IMFINZI · Oncology · in-kind Company’s descriptionJournal Article | $68.49 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $11,648 in research payments for these studies, mostly to the institutions running them.
- Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)
AbbVie Inc. · Active, not recruiting · NCT05822752 - M24-147 - Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.